false 0001157075 0001157075 2026-11-15 2026-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2026

 

PHARMACYTE BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada 001-40699 62-1772151
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3960 Howard Hughes Parkway, Suite 500
Las Vegas
, Nevada
89169
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code: (917) 595-2850

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, Par Value $0.0001 Per Share   PMCB  

The Nasdaq Stock Market LLC

         

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Consent and Warrant Exchange Agreement

 

On November 15, 2026, PharmaCyte Biotech, Inc. (the “Company”) entered into a Consent and Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with Q/C Technologies, Inc., formerly known as TNF Pharmaceuticals, Inc. (“Q/C”). Under the Warrant Exchange Agreement, the Company agreed to exchange 851,304 Series G Long-Term Warrants to purchase shares of Q/C’s common stock, par value $0.001 per share (the “Q/C Common Stock”), held by the Company, which were issued pursuant to that certain Securities Purchase Agreement, dated May 20, 2024, by and among Q/C and the purchasers party thereto, including the Company (such exchanged warrants, the “Exchange Warrants”), for an aggregate of 4,982,272 shares of Q/C Common Stock (the “Exchange Shares”) (the “Warrant Exchange”). The number of Exchange Shares was determined based on the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of the Q/C Common Stock on the last trading day prior to execution of the Warrant Exchange Agreement. The Company paid no additional consideration in the Warrant Exchange.

 

In addition, as majority holder of Q/C’s Series H Convertible Preferred Stock (the “Q/C Series H Preferred Stock”), the Company consented under the Warrant Exchange Agreement to an amendment to the Certificate of Designations of the Q/C Series H Preferred Stock that extends the maturity date of the Q/C Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Amendment”). The Company paid no consideration for the Series H Amendment.

 

Joshua N. Silverman, the Company’s Chief Executive Officer and Chairman of the Board of Directors, serves as the Chief Executive Officer of Q/C. The Company is also a holder of Q/C’s Series G Convertible Preferred Stock.

 

The Exchange Shares have not been registered under the Securities Act of 1933, as amended. Pursuant to the Warrant Exchange Agreement, upon the Company’s demand beginning 90 days after the Warrant Exchange, Q/C will be required to file a resale registration statement with the Securities and Exchange Commission to register the Exchange Shares for resale within 30 days after receiving such demand.

 

The foregoing description of the Warrant Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Warrant Exchange Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Consent and Warrant Exchange Agreement, dated November 15, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     
  PHARMACYTE BIOTECH, INC.
   
Date: November 19, 2026  
     
  By: /s/ Joshua N. Silverman
  Name: Joshua N. Silverman
  Title: Chief Executive Officer and President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3